Lilly’s Phase II Stumble Puts Merck’s BACE Inhibitor in Lead

Eli Lilly’s decision to halt a mid-stage trial of its beta secretase (BACE) inhibitor drug to treat Alzheimer’s disease puts Merck’s own BACE inhibitor candidate in the lead, analysts say. Lilly revealed late Thursday that it froze the Phase-II study of LY2886721 due to what it characterized as “abnormal liver biochemical tests” during routine monitoring.
Drug Industry Daily